Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
29. Januar 2025 17:30 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
$995.7 Million Spatial Genomics & Transcriptomics Market Global Forecast to 2029
29. Januar 2025 07:54 ET
|
Research and Markets
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Spatial Genomics & Transcriptomics Market by Product (Instruments, Consumables, Services), Technique (Transcriptomics (IHC, ISH), Genomics (LCM),...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
28. Januar 2025 08:29 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
28. Januar 2025 05:00 ET
|
ITM Isotope Technologies Munich SE
Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...
Delta-like Ligand 3 (DLL3) Targeted Therapies Market Research 2025: 1 Drug, Imdelltra (Tarlatamab) Available / 10 Drugs by Company, Indication and Phase / Approved Drug Dosage, Sales & Pricing Insight
23. Januar 2025 07:51 ET
|
Research and Markets
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's...
Precision Medicine Collaboration and Licensing Deals 2019-2024
16. Januar 2025 06:03 ET
|
Research and Markets
Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "Precision Medicine Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a...
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
15. Januar 2025 20:00 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
15. Januar 2025 16:01 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
13. Januar 2025 07:50 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Biosimulation Market Research Report 2024-2030: Expanding Applications in Defence, Industrial Bioprocessing, Nutraceuticals, and Agri-food Production
09. Januar 2025 07:38 ET
|
Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Biosimulation Market (2024 Edition): Analysis By Type (Services, Software), By Application, By Deployment Model Outlook, By Region, By Country: Market...